A new study published in Nature Communications has found that a blood test called AR-ctDETECT can distinguish between patients with advanced prostate cancer who have poor and favorable prognoses. The test, developed by researchers at the University of Minnesota Medical School and Duke University, analyzes circulating tumor DNA (ctDNA) in the blood of patients with advanced, metastatic prostate cancer.

Here’s a breakdown of the key findings:

• AR-ctDETECT identifies ctDNA in a significant portion of patients: The test detected ctDNA in 59% of patients with metastatic prostate cancer in a phase 3 clinical trial.
• ctDNA detection is linked to worse survival: Patients with detectable ctDNA had a significantly worse overall survival compared to those without. This is the first time this has been demonstrated in a phase 3 cohort.
• The test is designed for prostate cancer: AR-ctDETECT is specifically designed to detect genes relevant to prostate cancer and hormone resistance, particularly the androgen receptor and critical structural alterations not currently detected by other commercial tests.
• AR-ctDETECT offers critical prognostic insights: By identifying patients with poor prognoses, the test can help doctors better understand a patient’s cancer and predict disease progression, potentially leading to more personalized treatment plans.
• Future research: The research team plans to investigate whether the test can be used to predict patient outcomes in the context of specific treatments, which could be used in the future to guide optimal therapy.

The AR-ctDETECT test is a comprehensive panel focused on genes relevant to prostate cancer and hormone resistance. The study authors believe that incorporating genomic profiling into clinical decision-making may enhance personalized treatment strategies and inform the design of future clinical trials.

Source.